SNCA and Alzheimer disease: In subsequent studies, these outcomes have further been successfully translated to an animal model of Dementia with Lewy Bodies and of Alzheimer’s disease (AD), where treatment with montelukast restored memory, reduced the alpha-synuclein load, and impaired neuroinflammation [14,15].